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Abstract
Purpose—This study was aimed at developing and validating a quantitative multigene assay for 
predicting tumor recurrence after gastric cancer surgery.
Experimental Design—Gene expression data were generated from tumor tissues of patients 
who underwent surgery for gastric cancer (n=267, training cohort). Genes whose expression was 
significantly associated with activation of YAP1 (a frequently activated oncogene in 
gastrointestinal cancer), 5-year recurrence-free survival, and 5-year overall survival were first 
identified as candidates for prognostic genes (156 genes, P < 0.001). We developed the recurrence 
risk score (RRS) by using quantitative reverse transcription polymerase chain reaction to identify 
genes whose expression levels were significantly associated with YAP1 activation and patient 
survival in the training cohort.
Results—We based the RRS assay on six genes—IGFBP4, SFRP4, SPOCK1, SULF1, THBS, 
and GADD45B—whose expression levels were significantly associated with YAP1 activation and 
prognosis in the training cohort The RRS assay was further validated in an independent cohort of 
317 patients. In multivariate analysis, the RRS was an independent predictor of recurrence (hazard 
ratio, 1.6; 95% confidence interval, 1.02–2.4; P = 0.03). In patients with stage II disease, the RRS 
had a hazard ratio of 2.9 (95% confidence interval, 1.1–7.9; P = 0.03) and was the only significant 
independent predictor of recurrence.
Conclusions—The RRS assay was a valid predictor of recurrence in the two cohorts of patients 
with gastric cancer. Independent prospective studies to assess the clinical utility of this assay are 
warranted.
Keywords
Gastric cancer; Recurrence risk score; YAP1; Prognosis
INTRODUCTION
Gastric cancer (GC) is the third leading cause of cancer-related death worldwide (1) and 
surgery is the mainstay of treatment (2, 3). However, surgery alone benefits primarily 
patients with relatively early-stage disease. Multimodality therapies, consisting of surgery 
with adjuvant chemotherapy, radiation therapy, or both, have been established to improve the 
survival rates of patients (4–7).
Two recent phase III trials showed that more than 40% of patients with stage II or III GC 
experience a recurrence within 5 years after a curative D2 gastrectomy without adjuvant 
chemotherapy (6, 7). When chemotherapy was administered in conjunction with a D2 
gastrectomy, the absolute increase in 3-year recurrence-free survival (RFS) or disease-free 
survival was about 13–15% (6, 7). Given the very high clinical burden of GC worldwide, 
tools are clearly needed for predicting outcomes in patients after gastrectomy. Although 
conventional approaches using clinicopathological characteristics have been highly useful 
for prognostication, gene/genomics-based approaches will very likely give us better 
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prognostication and prediction of response to treatment (8–11). Understanding of the 
biological characteristics associated with the inherent heterogeneity of GC and identification 
of molecular markers reflecting that heterogeneity would significantly improve patient care.
One of the promising candidate markers of cancer recurrence might be YAP1. When Hippo 
signaling, a tumor suppressor pathway that is well conserved among species (12, 13), is 
reduced or absent, YAP1 enters the cell nucleus and increases transcriptional activation of 
genes involved in proliferation and survival of cancer cells (13, 14). The fact that a high 
expression level and amplification of YAP1 have been observed in many cancers, including 
GC (15–21), supports the idea that YAP1 is an oncogene.
In the current study, we found that activated YAP1 is significantly associated with poor 
prognosis in GC. We used a systematic multistep strategy to develop and validate a robust 
recurrence risk score (RRS) assay that, by reflecting underlying biological differences 
among tumors, can help identify patients at high risk of disease recurrence after surgery.
METHODS
Patients, Tissue Samples, and Gene Expression Data
Tumor tissues for the training cohort of GC patients (n = 267) had been obtained surgically 
between 1999 and 2006 at the Korea University Guro Hospital, Seoul; Kosin University 
College of Medicine, Busan; and Yonsei University Severance Hospital, Seoul; South Korea. 
All patients underwent a D2 gastrectomy. Of the 267 patients in training cohort, 155 had 
received adjuvant chemotherapy (either single-agent 5-fluorouracil or a combination of 5-
fluorouracil and cisplatin/oxaliplatin, doxorubicin, or paclitaxel). Tumor tissues for the 
validation cohort (n = 317) had been obtained surgically between 2000 and 2010 at the 
Seoul National University Bundang Hospital, Seongnam; and Yonsei University Severance 
Hospital, Seoul; South Korea (the validation cohort did not overlap with the training cohort). 
All patients in validation cohort also underwent a D2 gastrectomy and received adjuvant 
chemotherapy (either fluoropyrimidine alone [5-fluorouracil or S-1] or a combination of 5-
fluorouracil and cisplatin/oxaliplatin, or doxorubicin). Because any pretreatments can have 
significant effect on genome characteristics of tumors, pre-treated tissues were not included 
in training and validation cohorts. Patients were followed up - once every 3–6 months for 
first 3 years after surgery and once every 6 months after 3 years of surgery. Informed consent 
for sample collection had been obtained from all patients. The study protocol for 
retrospective analysis of tumor samples and clinical information was approved by the 
institutional review boards of The University of Texas MD Anderson Cancer Center 
(Houston, TX) and the five Korean hospitals where the tumor tissues had been obtained. 
Overall survival (OS) was defined as the time from surgery to death, and RFS was defined as 
the time from surgery to the first confirmed recurrence. Data were censored when a patient 
was alive without recurrence at last contact. Samples from the training cohort were fresh 
frozen tissues; samples from the validation cohort were formalin-fixed, paraffin-embedded 
(FFPE) tissues. Gene expression data from the 267 patients in the training cohort and GC 
cell lines MKN45 were generated as described in Supplementary Methods. Gene expression 
data from cell line are available from Gene Expression Omnibus data base (GSE41387). Cell 
line authentication was performed in 2011 using STR analysis conducted by Yonsei 
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University Severance Hospital DNA analysis facility. All of experiments and analyses were 
carried out at MD Anderson Cancer Center.
Statistical Analysis
BRB-ArrayTools software v4.3 was used for all statistical analyses (22). Gene expression 
differences were considered statistically significant if the P value was less than 0.005. 
Cluster analysis was performed with Cluster and TreeView v3.0 (23). Prediction of a 
patient’s class was made as described previously (24–28) and in the supplementary methods. 
Multivariate Cox proportional hazards regression analysis was used to evaluate independent 
prognostic factors associated with survival; the RRS (defined below), tumor stage, and other 
clinicopathological characteristics were included as covariates. A P value of less than 0.05 
was considered statistically significant. All statistical analyses were conducted in the R 
language environment (http://www.r-project.org).
Expression Analysis Using 48×48 Dynamic quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) Arrays
All expression analyses were carried out as described in the supplementary methods.
Development of the RRS
A multistep strategy was used to develop the RRS from the reference-normalized expression 
measurements. Six cancer genes were selected and grouped into three categories based on 
correlation between the results of microarray and qRT-PCR experiments and nonoverlapping 
biological characteristics as described in Results: stress response (GADD45B), cellular 
signaling (IGFBP4 and SFRP4), and interaction with the microenvironment (SPOCK1, 
SULF1, and THBS). To calculate the RSS, first, the expression level of each gene was 
multiplied by the Cox coefficient value derived from RFS data of the training cohort, 
generating a GENEcox value. Second, category scores were calculated by multiplying the 
total GENEcox value for each category by a contribution factor as follows: stress response 
score = GADD45Bcox × 0.4, cell signaling score = (IGFBP4cox + SFRP4cox) × 0.2, and 
microenvironment score = (SPOCK4cox + SULF4cox + THBS4cox) × 0.1. The contribution 
factors were set so that the three categories had approximately equal contributions to the 
RRS. Third, to generate a dynamic score range, each category score was transformed by 
applying a natural exponential function (ecategory score), and RRSraw was generated by 
summation of the transformed scores. Fourth, to generate a range of 0 to 100, the RRSraw 
was rescaled as follows: RRS = (RRSraw − 10) × 10, with RRS = 0 if RRS < 0 and RRS = 
100 if RRS > 100. RRSs were categorized as follows: <20, low risk; 20 to 40, intermediate 
risk; >40, high risk as indicated in Supplementary methods.
RESULTS
Activation of YAP1 Is Significantly Associated with Prognosis in GC Patients
Since YAP1 is frequently activated in many cancers, including GC (29–32), we first 
examined the clinical relevance of YAP1 activation in GC by generating gene expression 
data from GC cells overexpressing YAP1 (Supplementary Fig. 1). Further analysis of gene 
expression data identified 88 genes whose expression was significantly associated with 
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YAP1 activation (Supplementary Fig. 2A). We next tested the clinical significance of YAP1 
activation in human GC by comparing the YAP1 signature with gene expression data from 
GC tissue samples. Gene expression data from the 267 samples in the training cohort (Table 
1) were used for this analysis. An SVM algorithm (33) was applied to calculate the 
probability of YAP1 activation in each tumor sample (Fig. 1A). Briefly, YAP1 signature 
expression data from cell lines were used to generate an SVM classifier for estimating the 
likelihood that a particular gastric tumor belonged to the subgroup in which the YAP1 
signature was present (active YAP1 subgroup) or the subgroup in which the signature was 
absent (inactive YAP1 subgroup). When the tumors were thus categorized, a third of the 
patients (n = 88) were predicted to be classified into the active YAP1 GC subgroup. Kaplan-
Meier plots for the training cohort showed significant differences in RFS and OS (P < 0.001) 
between the two subgroups (Fig. 1B,C), strongly indicating that YAP1 may play an 
important role in the clinical course of GC. Further analysis showed that YAP1 signature is 
independent of stages (Supplementary Fig. 3).
Screening of Candidate Genes for Assessing Risk of Recurrence
Because all gene expression data were generated from fresh frozen tissues, which are not 
easily available in the clinic, and because the prediction model used a complex algorithm 
with long gene list from microarray data, which is not practical in the clinic, we sought to 
identify a small number genes predictive of GC recurrence by using easily available FFPE 
tissues. We used a two-step strategy to identify candidate genes for development of an easy-
to-use prognostic scoring system (Fig. 2). First, we identified candidate genes whose 
expression was significantly associated with RFS, OS, and activation of YAP1 in the training 
cohort; of the 824, 793, and 652 genes identified, respectively, 156 were associated with all 
three variables (Supplementary Fig. 2B). Second, we identified biologically nonredundant 
genes by an informatics approach. Because many of the 156 candidate genes could be 
involved in similar biological processes, we tried to identify a few genes that would 
represent diverse biological process. To avoid overrepresentation of particular biological 
processes or characteristics in the final gene set, we mapped these genes to biological 
processes in the Gene Ontology database (34) and selected top-ranked genes for each 
biological process (Supplementary Table 1). Of the 156 genes, 40 unique genes with 
minimum overlap in biological functions were selected (Supplementary Fig. 5).
Development of the RRS Assay
We next assessed the reproducibility of gene expression measurements in our microarray 
study by carrying out qRT-PCR experiments with RNAs that were randomly selected from 
the training cohort (48 samples). Reproducibility was high for the vast majority of genes. In 
particular, intermeasurement correlation was extremely high for 26 genes (r > 0.7 and P < 
1.0 × 10−7). On the basis of nonoverlapping biological characteristics, we selected six genes: 
IGFBP4 and SFRP4, cellular signaling; SPOCK1, SULF1, and THBS, interaction with the 
microenvironment; and GADD45B, stress response (Fig. 3, Supplementary Table 2). To 
generate RRSs in the range of 0 to 100 from the reference-normalized expression 
measurements, a four-step strategy was used (Supplementary Fig. 6A). As expected, the 
three RRS categories—low, intermediate, and high risk—were significantly associated with 
RFS (P = 0.02) and OS (P = 0.006) (Supplementary Fig. 6B and 6D). The combined low-
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intermediate risk category was also significantly associated with RFS (P = 0.005) and OS (P 
= 0.001) (Supplementary Fig. 6C and 6E). ROC analysis showed that overall performance of 
RRS for prognostication of patients is better than individual genes (Supplementary Fig. 8).
Validation of the RRS Assay
We next sought to validate the RRS assay in an independent cohort by using RNAs from 
FFPE tissues. We found that the continuous RRS was significantly associated with risk of 
recurrence as evidenced by their linear correlation with probability of recurrence within 5 
years postsurgery (Supplementary Fig. 9A). When patients in validation cohort were 
stratified according to RRS, the 5-year RFS rate was 82.5% for low-risk, 70.5% for 
intermediate-risk, and 58.1% for high-risk patients (P = 0.001; Fig. 4A). Likewise, two 
subgroup stratification showed significant association with RFS (P = 0.001; Fig. 4B). RRS 
was also significantly associated with OS (Fig. 4C and 4D). Furthermore, when patients with 
stage II/III disease (n = 264), who are routinely treated with adjuvant chemotherapy as 
standard treatment, were only included in analysis, association of RRS with prognosis 
remained significant (Supplementary Fig. 9B–9E). Taken together, these results clearly 
demonstrate the robustness of the RRS regardless of differences in the source of RNAs 
(fresh frozen or FFPE tissues) and its clinical relevance.
To evaluate the prognostic value of the RRS in combination with other clinical variables, we 
next carried out univariate and multivariate Cox proportional hazards regression analyses. 
Like TNM (tumor-node-metastasis) stage, which is a well-known predictor of RFS, RRS 
was a statistically significant indicator of RFS (hazard ratio = 1.92, 95% confidence interval 
= 1.02–3.6, P = 0.04; univariate analysis) (Supplementary Table 3). In multivariate analysis, 
which included all clinicopathological variables with moderate association (P < 0.2), RRS 
remained a significant prognostic factor (hazard ratio = 1.6, 95% confidence interval = 1.02–
2.4, P = 0.03).
Because stage II GC is considered to be heterogeneous as reflected in lower recurrence rate 
than stage III but higher recurrence rate than stage I after D2 gastrectomy (6, 7, 35), we 
carried out a subset analysis in stage II disease. In multivariate analyses, RRS was a 
significant predictor of RFS (Table 2), providing independent predictive value beyond tumor 
stage and number of nodes examined. Taken together, our data strongly suggest that the RRS 
model measures underlying biological characteristics that are predictive of clinical outcomes 
and that are not captured by traditional clinical and pathological indicators.
DISCUSSION
In this study, we showed that YAP1 activation is significantly associated with poor prognosis 
in GC. Using a systematic multistep strategy, we developed a six-gene-based RRS assay that 
can identify patients at high risk for cancer recurrence after surgery by measuring underlying 
biological differences. The robustness of the RRS assay was validated in an independent 
cohort of 317 patients. Because the RRS system uses qRT-PCR on RNAs from FFPE tissues, 
it can be easily implemented in the clinic.
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Multigene assays are currently being investigated for their abilities to improve 
prognostication and prediction of treatment outcomes for various cancers. For example, the 
Oncotype DX Breast Cancer Assay (Genomic Health, Redwood City, CA) uses 21 genes (16 
recurrence risk-associated genes and 5 reference genes) that were identified from 250 
candidate genes using tumor recurrence data and FFPE tumor tissues (8). In this system, the 
mRNA expression level of each gene measured by qRT-PCR is used to generate a recurrence 
score. In a retrospective analysis of data from two clinical trials, the assay not only 
quantified risk of recurrence in patients with hormone receptor-positive, axillary lymph 
node-negative breast cancer (8) but also predicted the magnitude of the chemotherapy 
benefit (9). Another assay system, the Oncotype DX Colon Cancer Assay (Genomic Health), 
uses 7 recurrence risk-associated and 6 chemotherapy benefit-associated genes that were 
identified from 761 candidate genes (10). Clinical validation using stage II/III colon cancer 
clinical trial data showed that a recurrence score based on 7 genes was prognostic for 
recurrence, but a treatment score based on 6 genes was not predictive of benefit from 
adjuvant chemotherapy (11). All these recurrence score validation analyses were 
retrospectively conducted and thus could not give definitive conclusion. Prospective clinical 
trials to evaluate the clinical usefulness of these assays are under way.
To the best of our knowledge, no assay system that can potentially provide prognostic or 
predictive information to assist decision making for GC in clinics has been tested in clinical 
trials. In most existing multigene assays for GC, genes were selected using predefined 
candidate genes from the literature (36) or small scale screening of candidate genes (37). To 
overcome our previous analysis with smaller number of patients that did not well reflect 
biological characteristics of GC (37), we applied multi-step systematic strategy that may 
reflect underlying biology of GC and prognostic significance. In the current study, we found 
the robustness of the YAP1 signature in predicting GC recurrence after resection, which 
were in agreement with previous observations in other cancers (38–41). Therefore, we 
decided to develop an easy-to-use RRS assay that reflects underlying biological differences 
(YAP1 activation) in GC. We found that 156 genes were significantly associated with RFS, 
OS, and YAP1 activation. From the 156 candidate genes, we identified 6 recurrence risk-
associated genes on the basis of biological function and data reproducibility of gene 
expression measurements in qRT-PCR and microarray experiments. Notably, one of the six 
genes, GADD45B, was previously identified as one of recurrence risk-associated genes in 
colon cancer (10), suggesting that this gene may play a critical role in progression of 
gastrointestinal cancers in general.
The continuous RRS was linearly correlated with probability of recurrence, allowing 
classification of risk as low, intermediate, or high. The six-gene RRS assay was validated in 
an independent patient cohort, and the prognostic relevance of RRS was independent of 
other clinical variables. Given that the rate of recurrence for stage II GC after a D2 
gastrectomy alone is ~30% compared with >50% for stage III (6, 7, 35), the decision on 
whether adjuvant chemotherapy should be administered is more challenging in stage II than 
in stage III. The subset analysis clearly showed that the six-gene RRS assay can be used to 
stratify stage II patients according to recurrence risk. These findings suggest that the six-
gene RRS assay might help clinicians decide whether to administer adjuvant chemotherapy 
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to patients after gastrectomy. Because our RRS assay uses qRT-PCR of RNA from FFPE 
tissues, we expect that it will be easily applicable in clinical practice.
The limitations of our study should be acknowledged. First, the study was performed 
retrospectively. Second, the sample of patients was heterogeneous and included patients with 
stage I or IV disease, who were not candidates for adjuvant chemotherapy. However, vast 
majority of patients were in stage II or III. In subset analysis with patients with stage II/III 
disease, who are candidates for adjuvant chemotherapy, association of RRS with prognosis 
remained significant. Third, the association between the RRS and benefit from adjuvant 
treatment could not be investigated because all patients in validation cohort received 
adjuvant chemotherapy. The potential of RRS in predicting benefit from adjuvant therapy 
after gastrectomy needs to be validated in future prospective study. Forth, since all patients 
in current study were from Korea, the applicability of our RRS system to patients with 
different ethnicities needs to be further investigated.
In conclusion, our robust RRS assay can help facilitate rational design of clinical studies by 
stratifying patients according to their risk of cancer recurrence. Prospective studies will need 
to be conducted to validate the clinical usefulness of the assay.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational relevance
Recurrence of gastric cancer occurs in up to 30%–40% of patients within 5 years after 
surgery. However, there are no clinically useful easy-to-use prognostication methods that 
can reliably predict the recurrence after surgery. Our data suggested that activation of 
YAP1, downstream target of Hippo pathway, is significantly associated with poor 
prognosis of patients with gastric cancer. Thus, we developed recurrence risk scores 
based on expression of six genes reflecting activation of YAP1 in gastric cancer. The 
recurrence risk score may help clinicians prognosticate recurrence of gastric cancer 
patients after surgery and might be useful in deciding whether to administer additional 
treatment to patients after surgery.
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Figure 1. Construction of prediction models using data from the training cohorts
(A) Schematic overview of the strategy used for constructing prediction models and 
evaluating predicted outcomes based on gene expression signatures. LOOCV, leave-one-out 
cross-validation. CON, control; SVM, support vector machine. (B & C) Kaplan-Meier plots 
of recurrence-free survival (RFS) and overall survival (OS) of patients stratified according to 
activation of YAP1 in tumors. P values were obtained by using the log-rank test. Censored 
data are indicated by the + symbol.
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Figure 2. Development and validation of the recurrence risk score assay
RFS, recurrence-free survival; OS, overall survival; GO, Gene Ontology database; RT-PCR, 
reverse transcription polymerase chain reaction
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Figure 3. 
Concordance of gene expression data from quantitative reverse transcription polymerase 
chain reaction (qRT- PCR) and microarray experiments.
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Figure 4. Significant association of recurrence risk scores with recurrence-free survival (RFS) in 
the validation cohort
(A & C) Patients were stratified into three groups on the basis of the indicated RRS cutoffs. 
int, intermediate. (B & D) Patients were stratified into two groups. P values were obtained 
by using the log-rank test. Censored data are indicated by the + symbol.
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Table 1
Clinical and Pathological Features of Gastric Cancer Patients
Variable
No. of Patients (%)
Training Cohort (n = 267) Validation Cohort (n = 317)
Sex
 Male 188 (70.4) 193 (60.1)
 Female 79 (29.6) 124 (39.9)
 NA 0 0
Age, median (range) 59 yr (28–83 yr) 58 yr (25–82 yr)
AJCC stage
 I 63 (23.6) 36 (11.3)
 II 48 (18.0) 136 (42.9)
 III 87 (32.6) 128 (40.4)
 IV 67 (25.1) 17 (5.4)
 NA 2 (0.7) 0
Tumor stage
 T1 22 (8.2) 18 (5.6)
 T2 89 (32.6) 169 (53.3)
 T3 120 (45.0) 127 (40.1)
 T4 29 (10.9) 3 (0.9)
 NA 7 (3.3) 0
Nodal stage
 N0 80 (30.0) 39 (12.3)
 N1 85 (31.9) 183 (57.8)
 N2 58 (21.7) 80 (25.2)
 N3 38 (14.2) 15 (4.7)
 NA 6 (2.2) 0
Lauren classification
 Intestinal 160 (59.9) 81 (25.5)
 Diffuse 72 (27) 155 (48.9)
 Mixed 19 (7.1) 17 (5.4)
 NA 16 (6.0) 64 (20.2)
Abbreviations: NA, information not available; AJCC, American Joint Commission on Cancer manual, 6th edition.
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Table 2
Multivariate Cox Regression Analyses of Recurrence Free Survival of Patients with Stage II disease in 
validation cohort (n = 136).
Variable
Multivariate Analysis
Hazard Ratio (95% CI) p value
Patient Sex (Male or Female) 0.97 (0.4–2.6) 0.96
Age (>70 years) 0.5 (0.07–4.0) 0.53
T stage (T3 or T2, T1) 1.4 (0.4–4.8) 0.61
N stage (N1, N2 or N0) 0.7 (0.2–2.5) 0.61
RRS (High or Int/Low) 2.9 (1.09–7.9) 0.03
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